Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) EPS (Basic) (2016 - 2025)

ProQR Therapeutics' EPS (Basic) history spans 5 years, with the latest figure at -$1.82 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 1603.02% to -$1.82 in Q4 2025 year-over-year; TTM through Dec 2025 was -$200210.3, a 40.31% decrease, with the full-year FY2025 number at -$0.47, down 36.17% from a year prior.
  • EPS (Basic) hit -$1.82 in Q4 2025 for ProQR Therapeutics, up from -$34465.6 in the prior quarter.
  • Over the last five years, EPS (Basic) for PRQR hit a ceiling of -$0.06 in Q4 2023 and a floor of -$104500.0 in Q1 2025.
  • Historically, EPS (Basic) has averaged -$36441.5 across 5 years, with a median of -$33781.8 in 2021.
  • Biggest five-year swings in EPS (Basic): surged 67.17% in 2023 and later crashed 1603.02% in 2025.
  • Tracing PRQR's EPS (Basic) over 5 years: stood at -$0.24 in 2021, then rose by 23.74% to -$0.19 in 2022, then surged by 67.17% to -$0.06 in 2023, then plummeted by 75.47% to -$0.11 in 2024, then crashed by 1603.02% to -$1.82 in 2025.
  • Business Quant data shows EPS (Basic) for PRQR at -$1.82 in Q4 2025, -$34465.6 in Q3 2025, and -$61242.9 in Q2 2025.